Amgen's Dazodalibep Sjögren's Study Hits Milestone as Investors Await Data
Amgen's phase 3 clinical study of Dazodalibep is nearing its data spotlight for Sjögren's Syndrome investors.
The study aims to evaluate the efficacy and safety of Amgen's experimental drug in patients with moderate-to-severe systemic disease activity. It tracks quality of life and safety, making it a key late-stage asset in Amgen's autoimmune portfolio.
Dazodalibep is given by intravenous infusion at two different dose levels against a placebo, reducing overall disease activity in Sjögren's patients and potentially offering a new treatment option in a field with limited approved therapies. The study uses a randomized design, where patients are assigned by chance to different groups, and it's double-blind with placebo control.
Key timing points matter for investors: the study was first submitted in October 2023, signaling the launch of phase 3 testing to the market. It is now listed as completed, and the latest update was filed on September 11, 2026, hinting that data cleaning and internal review may be underway before any public readout.